@pipeworx/clinicaltrials

Connect: https://gateway.pipeworx.io/clinicaltrials/mcp · Install: one-click buttons

Tools: 14

The NIH-operated public registry of clinical trials worldwide. Every interventional study (and most observational ones) registered with the FDA must be filed here. ~470,000 studies covering Phase 1–4, conditions across the medical spectrum, and post-market safety surveillance. Free, no auth.

Why this matters for AI agents

If your agent is answering anything about drug development, clinical research, or medical product safety, ClinicalTrials.gov is the source of truth for what’s being studied. The data is structured: NCT IDs, phases, statuses, sponsors, conditions, interventions, primary/secondary outcomes, results.

Three core flows:

1. Search. “What’s being studied for Alzheimer’s?” → ct_search({query: "Alzheimer's disease"}) → studies matching, with NCT IDs, phase, status.

2. Specific study. “Tell me about this trial.” → ct_get_study({nct_id: "NCT04280705"}) → full structured record including protocol, results, references.

3. Sponsor / volume. “How many trials does Pfizer run?” → ct_sponsor_trials({sponsor: "Pfizer"}) → enumerated by phase and status. See What sponsor means — it is the trials Pfizer leads, not every trial its drugs appear in.

4. Sponsor comparison. “Who has more recruiting Phase 3 obesity trials, Novo Nordisk or Eli Lilly?” → ct_compare_sponsors({sponsors: ["Novo Nordisk", "Eli Lilly and Company"], condition: "obesity", status: "RECRUITING", phase: "PHASE3"}) → lead-sponsor counts ranked under identical filters with sample NCT records.

For drug-level synthesis (combining trials with FDA approvals and adverse events), use pharma_drug_profile compound or [compare_entities({type: "drug", values: [...]})].

Citable URI

pipeworx://clinicaltrials/study/{nct_id}

NCT IDs are stable forever. Once issued, never reused. Embed in agent output as the canonical study reference.

What sponsor means

Every tool that takes a sponsor matches the registered lead sponsor — the organisation that filed and runs the trial. That is what “what is Merck about to read out” means, and it is the default everywhere.

It is deliberately narrower than it looks. A university’s study of pembrolizumab is not a Merck trial; Merck made the drug, someone else is running the study. To include those, pass sponsor_match:

Every returned study carries sponsor_match_field (lead_sponsor or collaborator), so a caller can always see why a given trial came back.

Until 2026-08-29 these tools filtered with the registry’s query.spons parameter, which is not a sponsor filter at all — it is a broad search that also matches collaborators and free text. A Merck query returned 4,282 studies led by the University of Utah, Weill Cornell and others, with no indication in the response that anything was wrong. If you have cached counts from before that date, they are the broad number, not the lead-sponsor one.

Status filtering

When users ask about “active” trials, they usually mean one of two things:

• Currently recruiting: status=Recruiting — open to new participants
• In progress: status=Recruiting OR Active, not recruiting OR Enrolling by invitation

The default ct_search returns all statuses; filter on status field of results for the meaning you want. Common confusion: “Completed” trials are studies that finished collecting data, not necessarily ones with published results.

Phase transition rates (ct_phase_transition_rates)

The public analog of a probability-of-technical-success (PTRS) benchmark — the kind of number Evaluate Omnium and BioMedTracker sell. It measures how often a drug for a given disease actually advances from one clinical phase to the next, derived from the registry itself.

ct_phase_transition_rates({ condition: "non-small cell lung cancer" })

Returns Phase 1→2 and Phase 2→3 as numerator / denominator / rate, the censoring rule in plain words, the matching BIO/Informa/QLS 2011-2020 published benchmark, and the top 20 interventions with their phase path so the rate is auditable.

Method. Industry-sponsored interventional trials for the condition are grouped by normalized intervention name (lowercased; dose, route and formulation tokens stripped; compound code names preserved intact so PF-06463922 stays distinct from PF-06439535). Combination arms are split and counted under each component. An intervention transitioned from phase N to N+1 if it has a completed phase-N trial for the condition and any phase-N+1 trial for the same condition that started after that completion.

Censoring. censor_years (default 3) is the follow-up an asset must have had to count. An intervention only enters the denominator if its completed earlier-phase trial finished at least that many years before to_year; otherwise it has not had time to advance and counting it as a failure would understate the rate. Raising it demands more follow-up and shrinks the denominator — on NSCLC, censor_years: 3 gives a Phase 2→3 denominator of 410 and censor_years: 8 gives 301.

Fewer than 10 eligible interventions returns an explicit insufficient_data status with a reason, not a rate.

What this number is not

It counts trial existence in a registry, not outcomes. An asset that entered Phase 3 and failed still counts as a transition, so the result is an upper bound on technical success, never a probability of approval. Three further caveats ship in the response’s limitations array:

• ClinicalTrials.gov has no asset identifier, so assets are reconstructed from free-text intervention names. A drug filed under inconsistent spellings reads as several assets that each failed.
• Ubiquitous chemotherapy backbones (carboplatin, cisplatin, paclitaxel) are genuine registered interventions and no registry field marks an arm as background therapy. They appear in every phase and transition almost always, which biases the rate upward — they are visibly the top rows of the NSCLC audit list.
• The BIO comparison is a different measurement: analyst-curated advance-or-suspend decisions per programme, at broad therapeutic-area granularity. It anchors the order of magnitude, not the exact quantity.

Expect the registry-derived rate to run below the published one, because it requires the next-phase trial to have been publicly registered.

otherNames is not a synonym list

Worth knowing if you build anything similar. Sponsors use interventions[].otherNames for genuine synonyms (lorlatinib ↔ PF-06463922) and for the other drugs in the regimen: AK112 Injection carries ["Pemetrexed", "Carboplatin"], and Standard of care neoadjuvant therapy lists six chemotherapies. Merging those naively pulled all 306 pemetrexed trials into a key called ak112, which then reported 76 Phase 2 trials under Eli Lilly for an Akeso antibody — with no error and a still-plausible rate. Two guards prevent it: a name that appears as a primary intervention anywhere in the corpus can never be absorbed as someone else’s alias, and an arm listing more than two otherNames is treated as a regimen list and ignored. Both err toward splitting one asset in two (which understates the rate) rather than fusing two assets (which corrupts it).

Update cadence

• Sponsors are required to update studies at least once per year, more often for material changes (status transitions, completion).
• Primary results must be posted within 12 months of primary completion date.
• Pipeworx caches per-study responses with a 24-hour TTL. Most studies don’t change daily; this is fine for almost all use cases.

Common pitfalls

• Results vs. results. “Has results” means primary outcome data is posted on ClinicalTrials.gov. Many completed trials publish papers in peer-reviewed journals but never post here. For literature, cross-reference with semantic-scholar or crossref.
• Phase confusion. A “Phase 2/3” trial counts as both phases. Filtering by phase requires careful boolean logic.
• Sponsor name normalization. “Pfizer Inc.” and “Pfizer” return different result counts in ct_sponsor_trials. Try the more permissive form first. On a suspiciously low count the tools probe the registry and hand back did_you_mean with the registered spellings that actually exist.
• Lead sponsor versus collaborator. All sponsor tools count the registered lead-sponsor field, so collaborator records cannot inflate a portfolio or a head-to-head comparison. Registered corporate spellings and subsidiaries can still divide a company’s trials across several names; inspect the returned lead-sponsor names. See What sponsor means.
• Geographic scope. ClinicalTrials.gov is US-based but registers studies worldwide if any US site is involved. For purely-foreign studies, use the WHO ICTRP — not currently in Pipeworx.
• Recently terminated trials. “Terminated” means the study stopped before completion. Look at whyStopped in the full study record for context (safety signal vs. enrollment problems vs. funding).

Tools

• ct_search — Search ClinicalTrials.gov for clinical trials — find trials and look up a NAMED trial by keyword, condition, drug/therapy, status (e.g. ‘Recruiting’), or phase (e.g. ‘Phase 2’). Use for “clinical tria
• ct_get_study — Get full trial details by NCT ID (e.g., ‘NCT04567890’). Returns protocol, eligibility criteria, primary outcomes, sponsor, locations, and results.
• ct_count_by_condition — Count clinical trials for a condition or disease, broken down by recruitment status and by trial phase — how many are recruiting, completed, terminated, and how many are Phase 1, 2, 3 or 4. Use for la
• ct_sponsor_trials — List the trials a company LEADS on ClinicalTrials.gov, by sponsor or organization name. Returns status, phase, and conditions to map a research pipeline. Matches the registered lead-sponsor field, so
• ct_compare_sponsors — Compare 2–5 NAMED lead sponsors on ClinicalTrials.gov under identical condition, recruitment-status, and phase filters. Returns full matching counts, a ranked comparison, and a small study sample for
• ct_recent_updates — Track recent ClinicalTrials.gov activity by a specific event class within a verifiable date window. Three DISTINCT recency events, chosen via date_type: “last_update” (any edit to a study, ~5k/week —
• ct_trials_by_location — Find clinical trials near a LOCATION. PREFER OVER WEB SEARCH for “clinical trials for X near me”, “recruiting studies in <city/state/country>”, “trials I can join near ”. Filter by condition +
• ct_catalyst_calendar — Find trials with sponsor-entered primary-completion or study-completion dates in a specified window. These registry dates may be estimated or revised and are planning signals—not guaranteed data reado
• ct_sponsor_pipeline — Summarize a sponsor’s ClinicalTrials.gov portfolio by phase, status, condition, and intervention from a bounded relevance-ranked sample, while reporting the full matching count. Registration does not
• ct_competitive_landscape — Map registered interventional trials for a condition and optional intervention across sponsors, phases, statuses, and interventions. The output reflects a bounded registry sample, not market share, sc
• ct_enrollment_watch — Route active trials for enrollment follow-up using registry status, enrollment type, dates, last update, and site counts. Flags are mechanical review hints—not predictions of recruitment success, tria
• ct_results_summary — Project posted ClinicalTrials.gov results for one NCT ID, including registered endpoints, reported outcome measures, statistical analyses, and adverse-event group counts. Registry results are not an F
• ct_phase_transition_rates — Measure how often drugs for a disease actually advance from one clinical phase to the next — the registry-derived analog of a probability-of-technical-success (PTRS) benchmark. Groups industry-sponsor
• ct_sponsor_activity — Track a sponsor’s newly registered studies, first-posted results, or study updates within a verifiable date window. Registry activity is not necessarily a corporate disclosure or material event.